Page last updated: 2024-12-10
mannotetraose
Description
mannotetraose: RN given refers to cpd with ((1-3)linkage alpha-D-mannopyranose)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-D-Manp : A tetrasaccharide comprised of four D-mannose residues connected by beta(1->4) linkages. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
mannotetraose : Any tetrasaccharide composed of 4 mannose moieties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (7)
Synonym |
mannotetraose |
CHEBI:62973 |
beta-d-manp-(1->4)-beta-d-manp-(1->4)-beta-d-manp-(1->4)-d-manp |
beta-d-mannopyranosyl-(1->4)-beta-d-mannopyranosyl-(1->4)-beta-d-mannopyranosyl-(1->4)-d-mannopyranose |
mannose, o-beta-d-mannopyranosyl-(1-4)-o-beta-d-mannopyranosyl-(1-4)-o-beta-d-mannopyranosyl-(1-4)-, d- |
d-mannose, o-beta-d-mannopyranosyl-(1-4)-o-beta-d-mannopyranosyl-(1-4)-o-beta-d-mannopyranosyl-(1-4)- |
Q27132313 |
Drug Classes (1)
Class | Description |
mannotetraose | Any tetrasaccharide composed of 4 mannose moieties. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (12.50) | 18.7374 |
1990's | 3 (18.75) | 18.2507 |
2000's | 3 (18.75) | 29.6817 |
2010's | 8 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |